HIV-1 Protease inhibitor monotherapy
Two studies, MONET and MONOI-ANRS, investigated the role of darunavir/ritonavir monotherapy in selected patients who were stable on HAART. The results of both studies suggest a potential role of PI monotherapy in selected patients using darunavir/ritonavir. More information: www.vircolab.com

mTB Diagnostics
Despite the alarming prevalence of HIV/m-TB coinfection, the introduction and expansion of anti-HIV therapy may be having a positive impact on mTB prevalence in sub-Saharan Africa.

HIV Resistance Testing
Though little was presented on HIV resistance compared to previous years, research from the group of Dr Richard Harrigan (British Columbia, Canada) focused on comparing Trofile (Monogram Biosciences) testing and Geno2Pheno (Max Planck Institute) genotypic algorithm-based testing in predicting virologic response to maraviroc (Pfizer), the only currently marketed CCR5 antagonist. This study was suggestive of the comparable utility of both approaches.

HIV Pipeline
Most of the IAS coverage on new compounds focused on GSK-364735 (GlaxoSmithKline/Shionogi & Co), a second-generation integrase inhibitor with reported high potency and acceptable tolerability profile, potentially without an overlapping resistance profile to existing marketed or in-development compounds.

Virco Presentations:
Virco BVBA presented one poster and one oral symposium presentation during IAS, these can be found at: Conferences & Poster Downloads www.vircolab.com